First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
The grant is designated for the research and development of Pyronaridine
Subscribe To Our Newsletter & Stay Updated
